Insights into Multiple Myeloma: Immune Microenvironment, Disease Mechanisms, and Therapeutic Innovations

Multiple myeloma (MM) remains a hematologic malignancy characterized by progressive immune dysfunction and the emergence of therapeutic resistance despite substantial recent advances in treatment. The transition from monoclonal gammopathy of undetermined significance (MGUS) to symptomatic MM is associated with coordinated immune dysfunction across innate and adaptive immune compartments. Single-cell and spatial profiling technologies reveal that immune abnormalities emerge at precursor stages and intensify during progression, including T-cell exhaustion, expansion of regulatory T cells, natural killer cell dysfunction, and impaired antigen presentation by dendritic cells. The cancer immunoediting framework, encompassing elimination, equilibrium, and escape phases, provides a unifying paradigm for understanding tumor-immune coevolution in MM. Disease complexity is further compounded by pronounced spatial and temporal heterogeneity. Multi-region sequencing studies demonstrate anatomically distinct clonal architectures and immune microenvironments within individual patients, contributing to variable therapeutic responses and facilitating immune escape. Current immunotherapies, including immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, chimeric antigen receptor (CAR) T-cell therapies, and bispecific antibodies, have transformed the therapeutic landscape of MM. Nevertheless, durable disease control remains limited by convergent resistance mechanisms, including antigen modulation, T-cell dysfunction, and persistent microenvironmental immunosuppression. A comprehensive understanding of the immune-mediated resistance mechanisms, extending beyond tumor-intrinsic genetic alterations, is essential for the rational design of next-generation therapies. Accumulating evidence suggests that immune dysfunction is closely associated with disease evolution and treatment resistance in MM and may represent a potentially targetable contributor to these processes.

Authors

Publication Details

Journal
International Journal of Molecular Sciences
Published
2026-11-13
DOI
https://doi.org/10.3390/ijms272210183
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Insights into Multiple Myeloma: Immune Microenvironment, Disease Mechanisms, and Therapeutic Innovations

Keichiro Mihara, Takahiko Miyama
2 links
International Journal of Molecular Sciences
Multiple Myeloma Research and Treatments
article

Insights into Multiple Myeloma: Immune Microenvironment, Disease Mechanisms, and Therapeutic Innovations

Keichiro Mihara, Takahiko Miyama
article en

Abstract

Multiple myeloma (MM) remains a hematologic malignancy characterized by progressive immune dysfunction and the emergence of therapeutic resistance despite substantial recent advances in treatment. The transition from monoclonal gammopathy of undetermined significance (MGUS) to symptomatic MM is associated with coordinated immune dysfunction across innate and adaptive immune compartments. Single-cell and spatial profiling technologies reveal that immune abnormalities emerge at precursor stages and intensify during progression, including T-cell exhaustion, expansion of regulatory T cells, natural killer cell dysfunction, and impaired antigen presentation by dendritic cells. The cancer immunoediting framework, encompassing elimination, equilibrium, and escape phases, provides a unifying paradigm for understanding tumor-immune coevolution in MM. Disease complexity is further compounded by pronounced spatial and temporal heterogeneity. Multi-region sequencing studies demonstrate anatomically distinct clonal architectures and immune microenvironments within individual patients, contributing to variable therapeutic responses and facilitating immune escape. Current immunotherapies, including immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, chimeric antigen receptor (CAR) T-cell therapies, and bispecific antibodies, have transformed the therapeutic landscape of MM. Nevertheless, durable disease control remains limited by convergent resistance mechanisms, including antigen modulation, T-cell dysfunction, and persistent microenvironmental immunosuppression. A comprehensive understanding of the immune-mediated resistance mechanisms, extending beyond tumor-intrinsic genetic alterations, is essential for the rational design of next-generation therapies. Accumulating evidence suggests that immune dysfunction is closely associated with disease evolution and treatment resistance in MM and may represent a potentially targetable contributor to these processes.

International Journal of Molecular SciencesVol. 27(22)
Good health and well-being
Multiple Myeloma Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon